Response of spinal myoclonus to a combination therapy of autogenic training and biofeedback
© Sugimoto et al; licensee BioMed Central Ltd. 2007
Received: 14 June 2007
Accepted: 12 October 2007
Published: 12 October 2007
Clinical evidence indicates that certain types of movement disorders are due to psychosomatic factors. Patients with myoclonic movements are usually treated by a variety of therapeutic agents. Autogenic training (AT), a recognized form of psychosomatic therapies, is suitable for certain types of neurological diseases. We describe a patient with myoclonus who failed to respond to conventional medical therapy. His symptoms were exaggerated by psychogenic factors, especially anger.
A 42-year-old man was admitted to our hospital, Preventive Welfare Clinic, for severe paroxysmal axial myoclonus of the left shoulder and abdominal muscles. The initial diagnosis was "combination of spinal segmental myoclonus and propriospinal myoclonus". The myoclonic movements did not occur during sleep but were aggravated by bathing, alcohol drinking, and anger. Psychological examination indicated hostile attribution. Although considered not to be a case of psychogenic myoclonus, a "psychogenic factor" was definitely involved in the induction of the organic myoclonus. The final diagnosis was "combination of spinal segmental myoclonus and propriospinal myoclonus accompanied by features of psychosomatic disorders". The patient underwent psychosomatic therapy including AT and surface electromyography (EMG)-biofeedback therapy and treatment with clonazepam and carbamazepine.
AT and EMG-biofeedback resulted in shortening the duration and reducing the amplitude and frequency of the myoclonic discharges.
Psychosomatic therapy with AT and surface EMG-biofeedback produced excellent improvement of myoclonic movements and allowed the reduction of the dosage of conventional medications.
There is clinical evidence that indicates that certain types of movement disorders are due to not only organic lesions but also related to psychosomatic factors [1–5]. Psychosomatic disorders (PSD) is a term used to describe a syndrome in which symptoms are aggravated by psychological factors. Patients with myoclonic movements are usually treated by a variety of therapeutic agents such as anticonvulsants and benzodiazepines because of their sedative effects [6–12]. On the other hand, autogenic training (AT) is considered an effective therapy for patients with hypertension, insomnia, headache, Raynaud's disease, skin disorders, anxiety  and pain . In neurological diseases, one case report showed that myoclonus secondary to anoxic encephalopathy was reduced by autogenic relaxation and electromyography (EMG) biofeedback . This case is the second report of successful improvement of myoclonus by AT.
A patient with myoclonus was referred to our hospital, Preventive Welfare Clinic, from another hospital after failure to respond adequately to medical therapy. We did a combination treatment of AT and biofeedback. Surface EMG during AT was recorded to monitor myoclonic discharge. AT-surface EMG therapy can provide a visual negative biofeedback effect (EMG-Biofeedback). In this report, we describe a patient with spinal myoclonus in whom AT-EMG-Biofeedback combination therapy resulted in excellent improvement of symptoms.
A 42-year-old man was admitted to our hospital for severe paroxysmal axial myoclonus of the left shoulder and abdominal muscles. The patient had been quite well and was a member of a self-defense force team until he developed spontaneous involuntary movements about 20 times per minute. The myoclonic movement gradually involved muscles of the left trunk, left lower extremity and right extremities within one month. The myoclonic movement did not occur during sleep but worsened upon taking a bath, drinking alcohol, and whenever the patient was angry. The patient was first admitted to a University hospital and diagnosed as "combination of spinal segmental myoclonus and propriospinal myoclonus" . The patient was treated with clonazepam (3.5 mg/day) and carbamazepine (400 mg/day). However, this treatment had no major effect on the symptoms. The condition worsened after discharge. Tapping anywhere on the body, including the face and spine, with a neurological hammer induced myoclonic contractions. The patient visited another medical clinic because of dissatisfaction with the medical treatment. A few years later, the patient was referred to our hospital, Preventive Welfare Clinic, for consultation.
On admission, physical and neurological examinations showed no abnormal findings apart from the myoclonic involuntary movements. Routine laboratory tests and MRI study of the cervical and thoracic spinal cords showed no abnormal findings. The myoclonus consisted of continuous rhythmic muscle contractions of the thoracic and abdominal muscles bilaterally, with left-side predominance. Tapping on certain points on the body, for example the left pectoralis major muscle or spine, with a neurological hammer induced myoclonic discharge. However, sound or light stimulation and elicitation of tendon reflex did not induce the myoclonic discharge. Medical history was negative for major accidents such as trauma and fever, and there was no change of working circumstances after the patient developed the myoclonic movements. Based on the description of anger-elicited worsening of myoclonic movements, the patient underwent a battery of psychological tests. The hysteria scale on the Minnesota Multiphasic Personality Inventory (MMPI) was very high (T score = 78). In the Cook-Medley Hostility Scale, the hostility and cynicism scales were high (above the average scale + SD). The score on the Cornel Medical Index (CMI) was within normal range, but the hostility scale was high.
Although clonazepam, carbamazepine, and other sedative medications were used at relatively high doses, the treatment failed to control the myoclonic movements. While it was concluded that the myoclonus was due to organic disease, anger/rage was associated with worsening of symptoms and the patient seemed to have a hostile character. Psychogenic myoclonus is known as a cause of movement disorders. Although this patient was not considered a case of psychogenic myoclonus, a "psychogenic factor" was definitely involved in the induction of the myoclonus. Our final diagnosis was a "combination of spinal segmental myoclonus and propriospinal myoclonus accompanied by features of psychosomatic disorders". Accordingly, we tried psychosomatic therapy; a combination of AT and EMG-biofeedback therapy, to reduce myoclonic movement and drug dosage.
Autogenic Training (AT)
AT was used for therapy as described previously . First, we described the significance of the AT effect, adaptation to AT, and how to perform AT, using a cassette tape. The patient started AT for 5 min, three times every day without changing the medications.
Duration and amplitude of myoclonic discharge during AT performance
Left major pectoral muscle
Left abdominal rectal muscle
0.61 ± 0.07
0.41 ± 0.06*
0.61 ± 0.10
0.27 ± 0.08*
1163 ± 410
283 ± 145*
862 ± 285
159 ± 56*
Psychogenic myoclonus is a recognized etiology of movement disorders. The characteristic features of psychogenic myoclonus are: 1) clinical features incongruous with organic myoclonus, 2) evidence of underlying psychopathology, 3) improvement with distraction, and 4) the presence of incongruous sensory loss or false weakness . Since our case was not consistent with criteria 2 and 4 above, this patient was not diagnosed as psychogenic myoclonus. In fact, this patient did not show spontaneous remission and placebo response. However, the myoclonus was worsened by bathing, alcohol consumption, and anger, and it disappeared during sleep. When psychogenic factors are suspected of influencing the symptoms, a psychosomatic approach should be considered as an optional therapy. In our case, we were able to reduce the dosages of medications from 3.5 mg/day of clonazepam and 400 mg/day of carbamazepine on admission to 2 mg/day of clonazepam only on discharge. After repetitive AT training and EMG-biofeedback therapy, the patient emphasized that he became more calm and that he was able to control his emotions. This awareness must have been significant to him.
Only one report has described the use of autogenic training with EMG biofeedback therapy and that such a protocol reduced the myoclonus, which was induced by anoxic encephalopathy . Though myoclonus is a neurological disease, a psychosomatic approach should be considered as an optional therapy, especially for patients with psychogenic factors known to enhance the symptoms.
Our patient with spinal myoclonus responded well to the combination therapy of AT and surface EMG-Biofeedback. Such therapy reduced the duration, amplitude, and frequency of myoclonic jerks and, consequently, we were able to reduce the dosage of clonazepam and carbamazepine.
This work was carried out at the Kansei Fukushi Research Center of Tohoku Fukushi University, Sendai, Japan, supported by "Academic Frontiers" Project for Private Universities: a matching fund subsidy from the Ministry of Education, Culture, Sports, Science and Technology of Japan (2004–2008).
Written consent for publication was obtained from the patient.
- Barbero-Aguirre P: Movement disorders: dystonias which are apparently psychosomatic. Torsion dystonias. Rev Neurol. 1999, 28 (Suppl 2): S192-S194.PubMedGoogle Scholar
- Deuschl G, Koster B, Lucking CH, Scheidt C: Diagnostic and pathophysiological aspects of psychogenic tremors. Mov Disord. 1998, 13: 294-302. 10.1002/mds.870130216.View ArticlePubMedGoogle Scholar
- Schmidt S, Wisser R, Heitmann R: Psychosomatic aspects of focal dystonia: two case reports. Psychother Psychosom Med Psychol. 1994, 44: 247-250.PubMedGoogle Scholar
- Cummings JL: Psychosomatic aspects of movement disorders. Adv Psychosom Med. 1985, 13: 111-132.View ArticlePubMedGoogle Scholar
- Wischnewski J: Choreatic movement disorders as a psychosomatic syndrome. Z Psychosom Med Psychoanal. 1978, 24: 87-89.PubMedGoogle Scholar
- Wheless JW, Sankar R: Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia. 2003, 44 (Suppl 11): 27-37. 10.1046/j.1528-1157.44.s11.5.x.View ArticlePubMedGoogle Scholar
- Rivest J: Myoclonus. Can J Neurol Sci. 2003, 30 (Suppl 1): S53-58.View ArticlePubMedGoogle Scholar
- Wallace SJ: Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998, 29: 147-154. 10.1016/S0920-1211(97)00080-6.View ArticlePubMedGoogle Scholar
- Caviness JN: Primary care guide to myoclonus and chorea. Characteristics, causes, and clinical options. Postgrad Med. 2000, 108: 163-166. 169–172View ArticlePubMedGoogle Scholar
- Caviness JN: Myoclonus. Mayo Clin Proc. 1996, 71: 679-688.View ArticlePubMedGoogle Scholar
- Obeso JA: Therapy of myoclonus. Clin Neurosci. 1995, 3: 253-257.PubMedGoogle Scholar
- Okamoto Y, Ota K: Diagnosis and therapy of epilepsy and myoclonus. Nippon Rinsho. 1993, 51: 3008-3015.PubMedGoogle Scholar
- Linden W: Autogenic training: a narrative and quantitative review of clinical outcome. Biofeedback Self Regul. 1994, 19: 227-264. 10.1007/BF01721069.View ArticlePubMedGoogle Scholar
- Kanji N: Management of pain through autogenic training. Complement Ther Nurs Midwifery. 2000, 6: 143-148. 10.1054/ctnm.2000.0473.View ArticlePubMedGoogle Scholar
- Duckett S, Kramer T: Managing myoclonus secondary to anoxic encephalopathy through EMG biofeedback. Brain Inj. 1994, 8: 185-188.View ArticlePubMedGoogle Scholar
- Nakazato Y, Nomura K, Tomioka R, Shimazu K, Hamaguchi K: A case of spinal segmental myoclonus and propriospinal myoclonus: a neuroelectrophysiologic analysis. Rinsho Shinkeigaku. 1998, 38: 948-950.PubMedGoogle Scholar
- Keefe FJ, Surwit RS, Pilon RN: Biofeedback, autogenic training, and progressive relaxation in the treatment of Raynaud's disease: a comparative study. J Appl Behav Anal. 1980, 13: 3-11. 10.1901/jaba.1980.13-3.PubMed CentralView ArticlePubMedGoogle Scholar
- Monday K, Jankovic J: Psychogenic myoclonus. Neurology. 1993, 43: 349-352.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.